Sinohealth Holdings Limited
SEHK:2361 Stock Report
Sinohealth Holdings Future Growth
Future criteria checks 2/6 Sinohealth Holdings is forecast to grow earnings and revenue by 9.9% and 11.7% per annum respectively. EPS is expected to grow by 9.6% per annum. Return on equity is forecast to be 11.3% in 3 years.
Key information Healthcare Services earnings growth 34.8% Revenue growth rate 11.7% Future return on equity 11.3% Analyst coverage Low
Last updated 29 Aug 2024
Recent future growth updates
Show all updates
Sinohealth Holdings' (HKG:2361) Anemic Earnings Might Be Worse Than You Think Sep 30
Sinohealth Holdings Limited Announces Resignation of Wan Chuan as Joint Company Secretary Sep 10
First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in 1H 2023) Sep 02
Consensus EPS estimates fall by 14% Aug 29
Sinohealth Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024 Aug 16
Sinohealth Holdings Limited Declares Final Dividend for the Year Ended December 31, 2023 Jun 19
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 27
Sinohealth Holdings Limited, Annual General Meeting, Jun 19, 2024 Mar 30 Sinohealth Holdings Limited, Annual General Meeting, Jun 19, 2024
Sinohealth Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024 Mar 19
Investor sentiment improves as stock rises 19% Dec 26
Consensus revenue estimates decrease by 11%, EPS upgraded Sep 01
First half 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.01 in 1H 2022) Aug 28
New major risk - Revenue and earnings growth Aug 26
Sinohealth Holdings Limited to Report Q2, 2023 Results on Aug 25, 2023 Aug 16
Investor sentiment improves as stock rises 21% Jun 30
Sinohealth Holdings Limited Declares Final Dividend for the Year Ended 31 December 2022 Jun 20
Weak Statutory Earnings May Not Tell The Whole Story For Sinohealth Holdings (HKG:2361) Apr 28
Investor sentiment improves as stock rises 16% Apr 28
Sinohealth Holdings Limited Just Recorded A 240% EPS Beat: Here's What Analysts Are Forecasting Next Apr 02
Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 31
Investor sentiment improves as stock rises 16% Feb 27
Investor sentiment improved over the past week Dec 06
Investor sentiment deteriorated over the past week Nov 21
High number of new and inexperienced directors Nov 16
Investor sentiment deteriorated over the past week Oct 28
Investor sentiment improved over the past week Sep 23
First half 2022 earnings released Sep 03
Investor sentiment deteriorated over the past week Aug 31
Sinohealth Holdings Limited to Report First Half, 2022 Results on Aug 29, 2022 Aug 18
Sinohealth Holdings Limited has completed an IPO in the amount of HKD 402 million. Jul 12
Insufficient new directors Jul 12
Earnings and Revenue Growth Forecasts SEHK:2361 - Analysts future estimates and past financials data (CNY Millions) Date Revenue Earnings Free Cash Flow Cash from Op Avg. No. Analysts 12/31/2026 585 115 N/A 108 1 12/31/2025 525 102 N/A 91 1 12/31/2024 438 78 N/A 75 1 6/30/2024 411 96 49 51 N/A 3/31/2024 403 99 62 65 N/A 12/31/2023 396 102 76 79 N/A 9/30/2023 388 101 75 79 N/A 6/30/2023 380 100 74 78 N/A 3/31/2023 369 78 51 55 N/A 12/31/2022 357 56 28 33 N/A 9/30/2022 348 61 24 28 N/A 6/30/2022 338 66 20 23 N/A 3/31/2022 331 72 39 41 N/A 12/31/2021 324 79 57 60 N/A 12/31/2020 202 68 60 62 N/A 12/31/2019 178 56 53 58 N/A
Show more
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2361's forecast earnings growth (9.9% per year) is above the savings rate (2.3%).
Earnings vs Market: 2361's earnings (9.9% per year) are forecast to grow slower than the Hong Kong market (11.9% per year).
High Growth Earnings: 2361's earnings are forecast to grow, but not significantly .
Revenue vs Market: 2361's revenue (11.7% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 2361's revenue (11.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2361's Return on Equity is forecast to be low in 3 years time (11.3%).
Discover growth companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
